Deferiprone, efficacy and safety

[1]  A. Hoffbrand,et al.  Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.

[2]  A. Hoffbrand,et al.  Iron chelation therapy , 1997, Journal of internal medicine. Supplement.

[3]  G. Koren,et al.  Deferiprone-Induced Agranulocytosis , 1997, Clinical drug investigation.

[4]  M. Sacco,et al.  Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone) , 1997, British journal of haematology.

[5]  M. Kersten,et al.  Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial , 1996, Annals of Hematology.

[6]  B. Bhattacharya,et al.  Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia. , 1995, Indian pediatrics.

[7]  G. Kontoghiorghes.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases , 1993, Indian journal of pediatrics.

[8]  R. Puniyani,et al.  Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.

[9]  H. Pati,et al.  Current management of homozygous beta thalassemia. , 1991, Indian pediatrics.

[10]  J. Graziano,et al.  Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. , 1978, The Journal of pediatrics.

[11]  A. Hoffbrand,et al.  EFFECT OF DOSE, TIME, AND ASCORBATE ON IRON EXCRETION AFTER SUBCUTANEOUS DESFERRIOXAMINE , 1977, The Lancet.

[12]  Hall Rr,et al.  Auxiliary mechanical hand. , 1963 .